Merck + Co., Inc.

Xingfang Hong

Peter J Sinclair

Joung L Goulet

Sander G Mills

William H Parsons

Kathleen M Rupprecht

Jianming Bao

James B Doherty

Shouwu Miao

Frederick Wong

John E Stelmach

Meng-Hsin Chen

Dennis M Zaller

Julianne A Hunt

Rose M Cubbon

Swaminathan R Natarajan

Luping Liu

Florida Kallashi

Mark A Holmes

Helen M Armstrong

Richard Beresis

Richard T Cummings

David D Wisnoski

James E Thompson

Rowena D Ruzck

Mark G Steiner

Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.

Benzimisazo[4,5-f]isoquinolinone derivatives

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

Src kinase inhibitor compounds

Growing community of inventors

Westfield, NJ, United States of America

Xingfang Hong